Detection of Human Papillomavirus in Chronic Cervicitis, Cervical Adenocarcinoma, Intraepithelial Neoplasia and Squamus Cell Carcinoma

Mirzaie-Kashani, Elahe; Bouzari, Majid; Talebi, Ardeshir; Arbabzadeh-Zavareh, Farahnaz

doi:10.5812/jjm.9930

Cited by 13 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 6 ] Another study found that 78 of 79 patients with chronic cervicitis tested positive for HPV. [ 8 ] In accordance with these studies, we found that before treatment, approximately 80% of patients were diagnosed with cervicitis and vaginitis, suggesting that HPV infection may cause local mucosal damage and contribute to cervicitis and vaginitis.…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis

et al. 2018

View full text Add to dashboard Cite

Background:We evaluated the efficacy and safety of combined high-dose interferon (IFN) and red light therapy for the treatment of subclinical and latent human papillomavirus (HPV) infections.Methods:Ninety women diagnosed with subclinical or latent HPV infection were randomized to receive topical application of low-dose recombinant IFNα-2b (1 million IU), high-dose IFNα-2b (9 million IU), or a combination of high-dose IFNα-2b and red light therapy on the cervix and vagina. All patients received treatment once daily for 4 weeks. HPV titer was measured immediately and 4, 8, and 12 weeks after treatment to determine the rates of viral clearance and infection cure. Treatment of HPV-associated vaginitis and cervicitis was also evaluated.Results:Results showed that immediately and 4, 8, and 12 weeks after treatment, the HPV clearance rates and infection cure rates were higher in the high-dose IFN and combination groups compared to the low-dose IFN group. High-dose IFN and combination therapies were significantly effective against both low-risk and high-risk HPV infections. Although the cure rates for vaginitis and cervicitis were significantly higher in the high- compared to the low-dose IFN group, rates were even higher in the combination group compared to the high-dose IFN group. Mild adverse effects were reported by a very small subset of patients (3/30) in the combination group.Conclusions:This study suggests that combination of high-dose IFN and red light therapy is safe and effective against subclinical and latent HPV infections.

show abstract

Section: Discussionsupporting

confidence: 82%

“…It was reported that the rate of HPV infection in chronic cervicitis cases was 98.7% (78/79). [ 8 ] In addition, bacterial infections appear to facilitate persistent HPV infections. [ 9 ]…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…3 Most of the cervical carcinomas are associated with human papilloma-virus (HPV) as rate of HPV and HIV infection in chronic cervicitis cases is much higher as observed by Ealhe, Atsuki et al in his study of CSC noticed that interactions between MSCs and tumor cells in tumor tissues could become a new cancer therapy target. [7][8][9][10] Autologus stem cell therapy can emerge as a potential treatment strategy for chronic cervicitis, with promising result for inflamed and damaged cervical tissue. As treatment with AASCs showed reversal of chronic inflammatory changes with healing of erosions, improved symptoms and better cervical health with improved quality of life and well-being, in long term prevention from Ca Cervix is expected.…”

Section: Discussionmentioning

confidence: 99%

Chronic cervicitis: role of adult autologus stem cells

Jain¹,

Jain²

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Stem cells are biological cells found in all multi-cellular organisms and capable to differentiate into diverse specialized cell types and self-renew to produce more stem cells. Stem cells act as immuno-modulatory, angiogenetic, cell repairing and cell protecting agents. They also have strong anti-inflammatory effect due to paracrine action of trophic factors release. Chronic cervicitis is very common disease of adult women worldwide, chronic infection and inflammation of the cervix is hard to cure with high recurrence rate leading to long term consequences like pelvic inflammatory disease, infertility, ectopic pregnancy, chronic pelvic pain, increased predisposition to HPV and HIV infection and even can be a precursor of cervical cancer.Methods: To show the therapeutic and symptomatic benefits of these cells in chronic cervicitis we injected 10 patients with adult autologus stem cells (AASCs) locally in the cervix, and PRP, growth factors IV. All the cells were harvested from bone marrow after bone marrow aspiration.Results: Clinical benefits were evident on follow up visits in the entire treated patient. All the patient had shown improvement in symptoms like continuous malodourous discharge, dyspariunea, pelvic pain and pressure, backache, itching and burning, post coital bleeding.Conclusions: Present study have shown that AASCs and growth factors is a safe effective ethical and viable option not only to cure the disease but also in improving the quality of life of a woman and protecting her from its significant consequences.

show abstract

“…We have also observed a low frequency of HPV infection (HPV [4.6%]; HPV16 [2.3%]; HPV18 [0%]) and no coexistence of the investigated pathogens in the cervicitis patients. The prevalence of HPV in cervicitis has shown an inconsistent pattern world-over, as observed in Korea (HPV [56.8%]; HPV16 [10.6%]; HPV18 [6.8%)]) [51], Iran (HPV [98.7%]) [52] and Greece (HPV [36%]; HPV16 [12%]; HPV18 [15%]) [53]. Although our data suggest no significant involvement of HPV in cervicitis; however, women when presented with cervicitis, should also be investigated for the presence of HPV, as the presence of HPV in cervicitis may serve as a compounding factor towards cervical carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

Association of TLR4 and TLR9 gene polymorphisms and haplotypes with cervicitis susceptibility

et al. 2019

View full text Add to dashboard Cite

Background Cervicitis is one of the major health problems amongst women caused by infection of various pathogens including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV) as well as human papillomavirus (HPV), and persistent cervical inflammation is one of the etiologic agents of cervical cancer. Toll-like receptors (TLRs) play an important role in the recognition and subsequent elimination of these pathogens. Variations in the Toll-like receptor genes influence susceptibility to pathogens as well as disease progression independently. Methods Ten single nucleotide polymorphisms, five each of TLR4 and TLR9 genes were analyzed among 130 cervicitis patients and 150 controls either using polymerase chain reaction-restriction fragment length polymorphism or allele specific-PCR. Results T . vaginalis infection was found at the highest frequency (30.7%) as compared to C . trachomatis (1.5%), N . gonorrhoeae (2.3%) and HPV (4.6%) infections in cervicitis patients. TLR4 rs11536889 CC (age-adjusted OR, 2.469 [95% CI, 1.499 to 4.065]; p < 0.001) and TLR9 rs187084 TC (age-adjusted OR, 2.165 [95% CI, 1.267–3.699]; p = 0.005) genotypes showed the higher distribution in cervicitis patients compared to controls. In addition, TLR4 rs11536889 C allele was shown to increase the risk of cervicitis (age-adjusted OR, 1.632 [95% CI, 1.132 to 2.352]; p = 0.009) compared to controls. The TLR4 haplotype GCA (OR, 0.6 [95% CI, 0.38–0.95]; p = 0.0272) and TLR9 haplotype GTA (OR, 1.99 [95% CI, 1.14–3.48]; p = 0.014) were found to be associated with decreased and increased risk of cervicitis respectively. Conclusions TLR4 and TLR9 polymorphisms, as well as haplotypes were shown to modulate the cervicitis risk.

show abstract

Detection of Human Papillomavirus in Chronic Cervicitis, Cervical Adenocarcinoma, Intraepithelial Neoplasia and Squamus Cell Carcinoma

Cited by 13 publications

References 15 publications

Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis

Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis

Chronic cervicitis: role of adult autologus stem cells

Association of TLR4 and TLR9 gene polymorphisms and haplotypes with cervicitis susceptibility

Contact Info

Product

Resources

About